Answers are grounded in this paper and cite their sources.
β -globinopathies (sickle-cell anemia and β-thalassemia) are the most common monogenic disorders worldwide that are potentially amenable to gene therapy. Proof-of-concept studies done 15 years ago, which showed correction of murine models of hemoglobinopathies, have gone through the rigors of preclinical safety and efficacy testing, and are now showing clinical promise both in β-thalassemia and sickle-cell anemia. Lentivirus-mediated gene replacement therapy with erythroid-specific expression of the globin gene appears safe thus far.
No takes yet. Share an insight, caveat, or question.
Punam Malik (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: